TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Tagrisso (Osimertinib)

Tagrisso / Osimertinib. Used for certain EGFR mutation-positive non-small-cell lung cancers.

PMDAproduct-level source2026-09label updated2026-10-05site verified
タグリッソ錠40mg/80mg · 40 mg / 80 mg
Japanese product photo · 40 mg / 80 mg · CareNet
Main useUsed for certain EGFR mutation-positive non-small-cell lung cancers.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
タグリッソ錠40mg/80mg
Brand
Tagrisso
Generic name
Osimertinib
Japanese generic name
オシメルチニブ
Chinese name
奥希替尼
Marketing authorization holder
アストラゼネカ株式会社
Strengths
40 mg / 80 mg
Dosage form
tablet
Therapeutic area
Oncology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Tagrisso is a third-generation EGFR tyrosine-kinase inhibitor, supplied as 40 and 80 mg tablets.

Read source section ↗
02

Mechanism of action

Irreversibly inhibits selected mutant EGFR signaling, including sensitizing mutations and T790M.

Read source section ↗
03

Japanese indications & eligibility

Japanese uses include selected EGFR-positive advanced/recurrent NSCLC, postoperative adjuvant treatment and maintenance after definitive chemoradiotherapy.

Read source section ↗
04

Administration & dose differences

Usually 80 mg once daily; clinicians may reduce or interrupt treatment. Adjuvant treatment is limited to 36 months in the label.

Read source section ↗
05

Adverse effects & key risks

Important risks include interstitial lung disease, QT prolongation, cardiac dysfunction and blood or serious skin abnormalities.

Read source section ↗
06

Contraindications & special populations

Contraindicated in pregnancy/possible pregnancy and ingredient hypersensitivity.

Read source section ↗
07

Drug interactions

Review CYP3A inducers, QT-prolonging drugs and relevant transporter substrates.

Read source section ↗
08

Assessment & monitoring

Confirm EGFR status and monitor lung symptoms, imaging, laboratory results and cardiac measures when indicated.

Read source section ↗
09

Storage & handling

Store at room temperature in the original packaging; the photo shows 40 and 80 mg blisters.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.